As transactions among major shareholders of Hanmi Pharmaceutical Group continue, tensions surrounding management control are rising.
On July 8, the Financial Supervisory Service's electronic disclosure system revealed that Hanmi Science announced the purchase of 3,604,799 common shares by its largest individual shareholder, Shin Dong-guk, chairman of Hanyang Precision. The acquisition price per share is set at 47,920 won, totaling approximately 172.7 billion won. Once the transaction is completed, Shin's stake will increase from 22.88% to 28.15%. Including his 6.95% stake in Hanyang Precision, Shin's total shareholding will amount to 35.10%.
This transaction is reportedly for shares held by Im Jong-yun, chairman of the Kori Group and the eldest son of the late founder, Im Seong-ki.
Since the founder's passing, conflicts over management control have persisted between the maternal side (Song Young-sook and Im Joo-hyun) and the siblings (Im Jong-yun and Im Jong-hoon).
Earlier, on July 2, Im Jong-hoon, CEO of Hanmi Precision Chemical, signed a contract to sell 1,709,788 shares (2.5%) of Hanmi Science for approximately 82.07 billion won. The buyer is reported to be a private equity fund.
At that time, Im stated that the transaction was a favorable decision for his mother, Song Young-sook, chairperson of Hanmi Pharmaceutical Group, and his sister, Im Joo-hyun, vice chairperson.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.